Cobepa, a privately-held investment company, acquired BioAgilytix, a leading provider of large molecule bioanalytical testing services, from Riverside Company for $280m. The acquisition by Cobepa will provide BioAgilytix with increased funding and resources to meet growing demand for its high-quality services, driven by its strong scientific reputation and leading expertise in biologics development. “We recognize BioAgilytix as a leader in the specialty area of large molecule bioanalysis, and with our support, its team will be fully equipped to help global pharmaceutical and biotech sponsors bring more large molecule drugs to market, faster,” said Peter Connolly, Managing Director, Cobepa North America.